Brainsway
Brainsway is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Brainsway.
Brainsway is a company.
Key people at Brainsway.
Key people at Brainsway.
BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders, specializing in its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform. Founded in 2003 and dual-listed on NASDAQ and the Tel Aviv Stock Exchange (TASE), the company develops advanced devices targeting conditions like major depressive disorder (including anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction, with ongoing trials for additional psychiatric, neurological, and addiction disorders.[1][2] It serves psychiatrists, doctors, hospitals, and medical centers, addressing unmet needs in patients unresponsive to traditional treatments by offering clinically proven, stigma-reducing options that improve access to mental healthcare.[1][2]
The company's growth momentum stems from its Burlington, MA, and Jerusalem offices, a robust body of clinical evidence, and a mission to make mental health reachable for all through bold neuroscience advancements.[1]
BrainsWay was founded in 2003 in Jerusalem, Israel, emerging from a vision to pioneer noninvasive brain stimulation technologies amid rising needs for effective mental health treatments.[1][2] Headquartered in Jerusalem with U.S. operations in Burlington, MA, the company has evolved from initial Deep TMS development to a commercial-stage leader with FDA clearances and global reach, dual-listed on NASDAQ and TASE.[1][2] Key pivotal moments include building an unparalleled clinical evidence base and expanding indications, driven by a commitment to unconventional thinking and patient impact—everyone knows someone affected by mental illness, yet awareness of options like Deep TMS remains low, fueling early traction through awareness efforts.[1]
BrainsWay rides the wave of neuroscience and digital therapeutics, capitalizing on growing mental health demands post-pandemic, where traditional medications and therapy fall short for millions.[1] Timing is ideal amid market forces like rising awareness of noninvasive brain stimulation, regulatory nods (e.g., FDA for key indications), and tech-health convergence enabling precise, stigma-free interventions.[1] It influences the ecosystem by advancing clinical standards, promoting Deep TMS as a mainstream option, and fostering inclusive mental healthcare access, potentially reshaping treatment paradigms for disorders affecting vast populations.[1]
BrainsWay is poised for expansion through new trial readouts in neurological and addiction spaces, leveraging its evidence moat to capture share in the booming neurostimulation market.[1] Trends like AI-enhanced personalization and global mental health investment will propel it, evolving its influence from niche innovator to ecosystem shaper in accessible neuroscience. As a dual-listed pioneer transforming lives where others can't, BrainsWay exemplifies how bold tech redefines mental health reach.[1]
